N,N-dimethyltryptamine and the pineal gland: Separating fact from myth

Interest has grown in the past two decades in the idea that the pineal gland produces N,N-dimethyltryptamine (DMT) and that endogenous DMT might mediate extraordinary phenomena such as dreaming, birth, and near-death out-of-body experiences. This surge in attention was catalysed in part by Rick Strassman's popular book and documentary DMT: The Spirit Molecule, and by public presentations that revived speculation about a ‘‘DMT gland’’. The pineal gland itself has a long cultural and philosophical history as the ‘‘third eye’’ or seat of the soul, which has predisposed some authors and lay audiences to accept the idea of pineal-derived DMT as an explanation for mystical experiences. Nichols sets out to examine the scientific evidence for endogenous DMT production in humans, with a particular focus on whether the pineal gland can synthesise and release DMT in physiologically relevant amounts. The review asks whether DMT is present in the body at concentrations sufficient to affect human consciousness, evaluates biochemical and pharmacological data bearing on DMT biosynthesis and transport, and considers plausible alternative neurochemical mechanisms that could account for the phenomenology attributed to endogenous DMT. The present article was motivated by a 2017 conference presentation and takes the form of a literature synthesis rather than a systematic review with prespecified search criteria.

This paper is a narrative review that synthesises anatomical, biochemical, pharmacological and physiological studies relevant to endogenous DMT and the pineal gland. Nichols draws on enzyme characterisations, tissue expression studies, animal microdialysis and radiolabelling experiments, human pharmacokinetic data from intravenous DMT administration, pinealectomy studies, and recent neurophysiological work on near-death brain activity. The review examines both primary experimental reports (for example, detection of trace DMT in rat pineal microdialysates) and secondary interpretations advanced in the literature. The extracted text does not report any formal, reproducible literature search strategy, inclusion/exclusion criteria, or risk-of-bias assessment, so the article should be regarded as a qualitative, hypothesis-driven synthesis rather than a systematic meta-analysis. When methodological limitations of individual studies are relevant to interpretation, the author discusses them (for example, issues with radiolabel tracers, lack of metabolite analysis, and the absence of MAO inhibition in some protocols). No new experimental data are presented in this paper.

Anatomical and endocrine context: The pineal gland is a very small neuroendocrine organ whose principal and conserved function is nocturnal melatonin secretion. Reported adult dimensions are about 5–9 mm by 1–5 mm by 3–5 mm and mean weights of roughly 100–180 mg; the adult gland rarely exceeds 0.2 g. Measured nightly melatonin output is on the order of tens of micrograms per day (reported averages ~21.6 µg/day in women and ~35.7 µg/day in men), with receptor affinities in the subnanomolar range (MT2 receptor affinity reported as 0.515 nM), emphasising that very small hormonal amounts can have physiological effects. INMT expression and capacity for DMT synthesis: The key methyltransferase for DMT biosynthesis, indolethylamine-N-methyltransferase (INMT), is present in many peripheral tissues (notably lung) and has been detected variably in brain, retina and pineal tissues in some species. Northern blot studies reported low or absent INMT mRNA in adult human brain, although immunohistochemical work in non-human primates detected INMT protein in spinal cord, pineal and retina. Enzymatic parameters indicate a relatively high K m for tryptamine (reported as ~270 µM), implying low affinity for tryptamine relative to substrates of many other neurotransmitter enzymes. DMT itself inhibits INMT (IC50 ~67 µM), so high local DMT concentrations would be self-limiting for further enzymatic production. Measured tissue levels and pharmacokinetic requirements: Very low concentrations of DMT have been detected in mammalian tissues and, in one report, in rat pineal microdialysate. However, pharmacokinetic and pharmacodynamic data from human intravenous administration indicate that psychoactive ‘‘breakthrough’’ into the phenomenological space produced by DMT corresponds to effect-site concentrations on the order of ~60 ng/mL (~318 nM). Nichols cites an infusion protocol that achieves ~100 ng/mL in a 75 kg subject using an initial bolus of 25 mg over 30 s followed by an infusion; this illustrates that on the order of tens of milligrams of DMT delivered rapidly are required to generate the characteristic psychedelic state. By comparison, the pineal’s nightly melatonin output is ~30 µg, about 1/1000 of the mass of DMT required to access that ‘‘DMT space’’. The extracted text emphasises the implausibility that the small pineal gland could suddenly synthesise and release ~25 mg of DMT within minutes. Brain uptake and putative accumulation mechanisms: Studies reporting elevated brain/plasma ratios for exogenous DMT after peripheral administration (rat brain/plasma ratios reported around 5.4, and similar findings with [11C]DMT) have been interpreted by some as evidence of active uptake or accumulation. Nichols notes methodological caveats: many studies did not assay intact DMT versus metabolites, some used modified radiolabelled analogues (for example 2-iodo-DMT) with altered physicochemical and pharmacological properties, and pretreatment with MAO inhibitors was often absent. Experiments using reserpine and pargyline claimed uptake into brain compartments, but reserpine produced negligible effect on subcellular distribution, arguing against synaptic vesicle storage in vivo. The review stresses that a brain/plasma ratio alone is not sufficient proof of active transport or vesicular accumulation. Transporter and receptor pharmacology: In vitro data indicate DMT can interact with monoamine transporters. One study reported inhibition of [3H]5-HT transport with a Ki of ~4 µM at the serotonin transporter (SERT), while a larger screening study identified DMT as a SERT-selective releaser with an EC50 reported as 114 nM. Even if DMT is a substrate for SERT or the vesicular monoamine transporter (vMAT), the more plausible pharmacological consequence is carrier-mediated release of serotonin rather than storage and regulated, action-potential-dependent exocytotic release of DMT. The S1R (sigma-1 receptor) has been proposed as an endogenous DMT target, but reported affinities are weak (KD ~14.75 µM) and are substantially higher than plasma concentrations reached in human IV dosing (reported peak ~0.478 µM), making physiological S1R activation by endogenous DMT unlikely under normal conditions. Evidence from pinealectomy, near-death and stress physiology: Experimental pinealectomy in rats produced no clear alterations in total sleep, REM sleep, NREM delta power or circadian rhythm amplitude; a rare human pinealectomy case report documented increased REM but no other overt behavioural abnormalities. Alternative mechanisms that could explain near-death or stress-associated altered states include release of endogenous opioid peptides (for example dynorphin acting at kappa-opioid receptors) and dramatic, rapid surges in classical neurotransmitters during asphyxia or cardiac arrest. Work from Borjigin’s laboratory in rats shows transient but marked increases in EEG gamma power and coherence at cardiac arrest alongside large cortical surges of norepinephrine (more than 30-fold within the first minute), serotonin (more than 20-fold within two minutes), dopamine (more than 12-fold within the first minute) and sustained increases in multiple neurotransmitters during asphyxia. Hypoxic/ischaemic glutamate release is also emphasised as a plausible cause of dissociative or out-of-body experiences; ketamine, which raises cortical glutamate, can produce similar phenomenology.

Nichols concludes that the preponderance of current evidence does not support the romantic notion that the pineal gland secretes physiologically relevant amounts of DMT to produce dreaming, birth or near-death psychedelic experiences. Trace amounts of DMT are detectable in mammalian tissues, and INMT is present in peripheral tissues and, to varying degrees, in some neural sites; however, enzymatic kinetics, measured tissue concentrations, and pharmacokinetic requirements for producing the full DMT psychedelic state argue against endogenous production at the necessary magnitude. The author highlights specific technical weaknesses in studies that have been used to support the ‘‘pineal DMT’’ hypothesis, including reliance on radiolabel measures without metabolite analysis, use of chemically modified analogues, absence of MAO inhibition where relevant, and failure to demonstrate bona fide vesicular storage or action-potential-dependent release of DMT. Rather than invoking large, rapid pineal secretion of DMT, Nichols presents alternative and better documented neurochemical mechanisms that could plausibly underlie vivid near-death and stress-related experiences: massive, transient increases in monoamine neurotransmitters (norepinephrine, serotonin, dopamine), dynorphin–kappa-opioid system activation, and excessive glutamate release during hypoxia/ischaemia. These phenomena are supported by animal neurophysiology showing transiently heightened cortical synchrony and neurotransmitter surges at cardiac arrest, and by known pharmacology linking 5-HT2A activation and glutamatergic perturbation to hallucinatory and dissociative states. The author also notes experimental gaps—such as the lack of definitive studies incubating radiolabelled DMT with synaptosomes under MAO-inhibited conditions or using reserpine to probe vesicular uptake—which, if performed, could more conclusively address questions of neuronal accumulation and storage. Finally, Nichols frames the arguments in a cautionary tone: the cultural and metaphysical appeal of a ‘‘DMT gland’’ has driven popular and speculative narratives, but the scientific data reviewed favour more conventional neurochemical explanations for altered states associated with stress and near-death. The extracted text does not report that the review applied systematic search methods, so the conclusions reflect a qualitative synthesis of the available experimental literature rather than a formal evidence-grade assessment.

Summarising the reviewed evidence, Nichols emphasises several points: other endogenous opioids can mediate euphoria and analgesia via mu and delta opioid receptors and dynorphin–kappa-opioid receptor signalling can shape stress-related altered states; asphyxiation or cardiac arrest can paradoxically produce transient brain activation with marked increases in neurotransmitters such as norepinephrine, serotonin and dopamine, the surge in serotonin potentially stimulating 5-HT2A receptors implicated in hallucinations; hypoxia-induced glutamate release can contribute to out-of-body and hallucinatory experiences, a mechanism congruent with the effects of drugs like ketamine; and, despite its appeal, the hypothesis that the pineal gland releases sufficient DMT to cause these altered states is not supported by current, well-substantiated data. More well-studied neurochemical systems provide more plausible explanations for out-of-body experiences than a large-scale pineal DMT release.